B95a cells use the signalling lymphocyte activation molecule (SLAM ; also known as CD150) as a cellular receptor, whereas the Edmonston strain and its derivative vaccine strains can use both SLAM and the ubiquitously expressed CD46 as receptors. Among the major target cells for MV, lymphocytes and dendritic cells are known to express SLAM after activation, but monocytes have been reported to be SLAM-negative. In this study, SLAM expression on monocytes was examined under different conditions. When freshly isolated from the peripheral blood, monocytes did not express SLAM on the cell surface. However, monocytes became SLAM-positive after incubation with phytohaemagglutinin, bacterial lipopolysaccharide or MV. Anti-SLAM monoclonal antibodies efficiently blocked infection of activated monocytes with a wild-type strain of MV. These results indicate that SLAM is readily induced and acts as a monocyte receptor for MV.
Measles virus (MV) is a member of the genus Morbillivirus of the family Paramyxoviridae and naturally infects humans and subhuman primates. Measles is one of the leading causes of childhood mortality, with roughly 1 000 000 measlesassociated deaths occurring worldwide per annum (Centers for Disease Control and Prevention, 1999) . Measles-related mortality has been attributed mostly to MV-induced immune suppression (Griffin & Bellini, 1996 ; Klagge & SchneiderSchaulies, 1999) .
Virus-receptor interaction plays an important role in virus tropism and pathogenesis (Schneider-Schaulies, 2000) . CD46 (also known as membrane cofactor protein) has been identified as a cellular receptor for vaccine strains of MV, such as the Edmonston strain (Do$ rig et al., 1993 ; Naniche et al., 1993) . It is expressed on all nucleated human cells and, accordingly, the Edmonston strain can infect almost any human cell line. In contrast, wild-type MV strains that are commonly isolated in Author for correspondence : Hiroko Minagawa.
Fax j81 92 642 6140. e-mail hmina!virology.med.kyushu-u.ac.jp the Epstein-Barr virus (EBV)-transformed marmoset B lymphocyte line B95a or human B cell lines are usually unable to use CD46 as a receptor and, thus, fail to infect many cell lines that are susceptible to the Edmonston strain (Bartz et al., 1998 ; Hsu et al., 1998 ; Lecouturier et al., 1996 ; Tanaka et al., 1998 ; Tatsuo et al., 2000 a) . Recently, we have shown that the signalling lymphocyte activation molecule (SLAM ; also known as CD150), a cell surface glycoprotein recognized by the monoclonal antibodies (MAbs) IPO-3 and A12 (Cocks et al., 1995 ; Sidorenko & Clark, 1993) , is a cellular receptor for both wild-type and vaccine strains of MV (Tatsuo et al., 2000 b) .
Unlike CD46, the known distribution of human SLAM is rather limited ; it was identified originally as a molecule expressed on activated B and T cells (Cocks et al., 1995 ; Sidorenko & Clark, 1993) . The use of SLAM as a receptor seems to serve well for MV as the virus grows better in activated cells rather than in resting ones (Hyypia$ et al., 1985 ; Joseph et al., 1975) . SLAM is also expressed constitutively on immature thymocytes, memory T cells and a proportion of B cells. Monocytes, natural killer (NK) cells (Aversa et al., 1997 ; Cocks et al., 1995 ; Sidorenko & Clark, 1993 ) and the myelomonocytic cell lines THP-1, U-937 and HL-60 (Aversa et al., 1997 ; Tatsuo et al., 2000 b) have little or no expression of SLAM. Dendritic cells (DCs) collected directly from blood express SLAM following activation via CD40 (Polacino et al., 1996) . A recent study also reported SLAM expression on monocyte-derived DCs (Ohgimoto et al., 2001) .
Besides T and B lymphocytes, MV has been shown to infect monocytes (Esolen et al., 1993 ; Joseph et al., 1975 ; Salonen et al., 1988) , macrophages (Helin et al., 1999 ; Kamahora & Nii, 1965) and DCs (Fugier-Vivier et al., 1997 ; Grosjean et al., 1997 ; Schnorr et al., 1997 ; Steineur et al., 1998) . Since all these cells may be responsible for systemic virus spread and MV-induced immune suppression, it is important to know how MV infects these cells. Lymphocytes and DCs may express SLAM as described above, whereas monocytes have been reported to be SLAM-negative. In this study, we examined the expression of SLAM on the monocyte cell surface under different conditions and the effects of anti-SLAM antibodies on MV infection of monocytes.
Peripheral blood mononuclear cells (PBMCs) were obtained from the leukocyte-enriched buffy coat of human peripheral blood by density gradient centrifugation at 600 g for 30 min 0001-8029 # 2001 SGM Fig. 1 . Expression of SLAM on CD14 + cells. Experiments were repeated with seven different individual samples and representative data from two individual samples are shown : one for (A-E) and another for (F-I). Gates were set for mononuclear cells (lymphocytes and monocytes) and data were collected from at least 10 000 events per tube. PHAstimulated PBMCs were stained with FITC-conjugated (abscissa) and PE-conjugated (ordinate) isotype control MAbs (A). Freshly isolated PBMCs (B) and PBMCs incubated for 24 h in medium alone (C, F) or containing PHA (D), LPS (E), control B95a inoculum (G), infectious MV (H) or UV-MV (I) were stained for CD14 (abscissa) and SLAM (ordinate). The Ichinose strain of MV was used for this experiment.
onto Histopaque-1077 (Sigma) and were washed with PBS. MV stocks of the B95a-isolated KA and Ichinose strains (Tanaka et al., 1998 ; Tatsuo et al., 2000 a, b ) and the Edmonston strain were prepared as described previously (Tanaka et al., 1998) . For virus growth, B95a cells (Kobune et al., 1990) were grown in RPMI 1640 supplemented with 10 % heat-inactivated foetal bovine serum, 0n18 % sodium bicarbonate, 10 mM HEPES and 50 µg\ml gentamicin. To prepare the control inoculum, B95a cells without infected MV were treated similarly. UV-inactivated MV (UV-MV) was prepared by irradiating the virus stock with a UV cross-linker (Stratagene) at 240 mJ (Minagawa & Yanagi, 2000) .
PBMCs were stained either immediately after isolation or 24 h after stimulation with one of the following reagents added to the growth medium : 5 µg\ml phytohaemagglutinin (PHA) (PHA-P ; Sigma), 10 µg\ml lipopolysaccharide (LPS) from Escherichia coli (O55 : B5 ; Sigma), MV with or without UV inactivation at an m.o. When freshly isolated PBMCs were examined, CD14 + cells comprising mostly monocytes were negative for SLAM (Fig.  1 B) , as reported previously (Cocks et al., 1995 ; Sidorenko & Clark, 1993) . While SLAM expression on CD14 + cells increased slightly after incubation in growth medium (Fig. 1 C,  F) , the majority of CD14 + cells became strongly SLAMpositive following stimulation with PHA (Fig. 1 D) . Stimulation with LPS also increased the proportion of SLAM-positive cells in the CD14 + cell population (Fig. 1 E) . Inoculation with either infectious MV (Fig. 1 H) or UV-MV (Fig. 1 I) SLAM expression on CD14 + cells. Control inoculum prepared from mock-infected B95a cells only slightly induced SLAM expression (Fig. 1 G) . Since MV infection does not alter significantly the amounts of EBV secreted in the supernatants of B95a cells (Kobune et al., 1990) , MV itself, but not EBV, must be largely responsible for this induction of SLAM. Induction of SLAM on CD14 + cells was observed reproducibly among seven donors after stimulation with PHA, LPS or UV-MV, prepared from two wild-type strains (KA and Ichinose). These results indicate that although freshly isolated monocytes do not express SLAM, they readily become SLAM-positive after activation.
To confirm that MV can infect monocytes by using SLAM as a receptor, we examined if anti-SLAM MAbs interfere with wild-type MV infection of PHA-stimulated monocytes. PBMCs were overlaid onto a discontinuous density Percoll (Pharmacia) gradient (75, 50n5, 40 and 30 %) and centrifuged at 1000 g for 20 min at 4 mC (Takamizawa et al., 1997) . The fraction with the lightest density was stimulated for 4 h with 5 µg PHA and then enriched further for monocytes by depleting T, B and NK cells as follows : cells were first incubated with mouse MAbs specific for CD3 (T cell marker), CD19 (B cell marker) and CD56 (NK cell marker) and then incubated with anti-mouse IgG covalently bound to paramagnetic polystyrene beads (Dynabeads ; Dynal). Magnetunbound cells were collected as purified monocytes and assessed for purity by flow cytometry. The percentage of CD14 + cells in the resultant population was 90 %, while contaminating T and B cells were both less than 1 %. These purified monocytes were pre-incubated with 10 µg\ml anti-SLAM MAb (IPO-3 ; Kamiya Biochemical) (Sidorenko & Clark, 1993) or control mouse IgG for 1 h, as described previously (Tatsuo et al., 2000 b) . Cells were then inoculated with either the KA or the Edmonston strain of MV at an m.o.i. of 2 TCID &! per cell. After 1 h of adsorption, cells were washed and incubated for 18 h in fresh growth medium. Following extensive washing, cells were evaluated for MV haemagglutinin (H) expression by flow cytometry, as described previously (Tatsuo et al., 2000 b) .
A large proportion of monocytes pre-treated with control mouse IgG expressed MV H protein on the cell surface following inoculation with the wild-type KA strain of MV (Fig.  2 A) . Monocytes pre-treated with IPO-3 hardly expressed H protein after inoculation with the KA strain. On the other hand, IPO-3 did not affect H protein expression on monocytes after inoculation with the Edmonston strain (Fig. 2 B) . This was expected as the Edmonston strain can use CD46 as well as SLAM to infect cells (Tatsuo et al., 2000 b) . The inability of IPO-3 to inhibit infection with the Edmonston strain in turn indicates that it inhibited infection of monocytes with the KA strain by blocking the virus-SLAM interaction but not by affecting the intracellular virus replication following entry.
In this report, we showed that monocytes, which were SLAM-negative upon isolation from the peripheral blood, readily became SLAM-positive following incubation of PBMCs with PHA, LPS, infectious MV or UV-MV. The stimulation protocols used in the present study were simple and short in the time-course, unlike those used for the generation of macrophages (Helin et al., 1999) or DCs (Ohgimoto et al., 2001 ) from monocytes, indicating that monocytes do not need to be highly differentiated to express SLAM. This suggests that monocytes that migrate to the sites of inflammation and\or microbial propagation in vivo may become SLAM-positive under the influence of various stimuli, thus becoming susceptible to MV. Our finding provides a solution for the paradox that monocytes are major target cells for MV (Esolen et al., 1993 ; Salonen et al., 1988 ), yet do not express the MV receptor SLAM (Cocks et al., 1995 ; Sidorenko & Clark, 1993) .
Anti-SLAM MAbs were shown to block infection of activated monocytes with the wild-type KA strain, indicating that SLAM indeed acts as a receptor for MV on monocytes. Some clinical isolates exclusively grown in PBMCs have been reported to use CD46 as a receptor (Manchester et al., 2000 a) . However, we and others have shown that even those strains that use CD46 as a receptor are also capable of using SLAM (Erlenhoefer et al., 2001 ; Hsu et al., 2001 ; Tatsuo et al., 2000 b) . Furthermore, we have shown that most viruses on throat swabs from measles patients use SLAM but not CD46 as a receptor (Ono et al., 2001) .
Thus, SLAM is present not only on activated T and B lymphocytes and DCs, but also on activated monocytes. The distribution of SLAM, broader than that reported previously, fits the known tropism of MV as well as the multifactorial nature of MV-induced immune suppression (Borrow & Oldstone, 1995) to which infection of DCs (Fugier-Vivier et al., 1997 ; Grosjean et al., 1997 ; Schnorr et al., 1997 ; Steineur et al., 1998) , interaction between viral proteins and cellular molecules (Manchester et al., 2000 b ; Marie et al., 2001 ; Schlender et al., 1996) and soluble factors such as IL-12 (Karp et al., 1996) may all contribute. Further studies on the distribution of SLAM on other targets of MV infection (e.g. epithelial cells, endothelial cells and the central nervous system) and the function of SLAM expressed on the cells of the immune system should deepen our understanding of the pathogenesis of MV.
